Case Study
ISSN: 3051-8830
Journal homepage: https://www.harrisonacademicpress.com/index.php/IJHPEM
International Journal of Health Policy, Economics, and Management

Harrison Academic Press

Impact of Value-Based Payment Models on Chronic Disease Management Outcomes: A Health Economics Evaluation

Fabbri S[1*], Stavrou K[2] and Christiansen I[3]

[1]*Department of Health Economics, University of Turin, Turin, Italy*
[2]*Department of Public Health, Aristotle University of Thessaloniki, Thessaloniki, Greece*
[3]*Department of Health Policy, University of Copenhagen, Copenhagen, Denmark*

ABSTRACT

Background: Fee-for-service reimbursement rewards service volume rather than the coordinated, longitudinal care that chronic diseases such as diabetes, cardiovascular disease, and chronic obstructive pulmonary disease require, prompting adoption of value-based payment (VBP) models intended to realign financial incentives toward cost and quality. Objective: This case study synthesizes health economics evidence on the impact of major VBP models - accountable care organizations (ACOs), global-budget contracts, condition-based bundled payments, and pay-for-performance (P4P) programs - on chronic disease management cost, quality, and care coordination outcomes. Methods: We conducted a case-based narrative synthesis of peer-reviewed evaluations of purposively selected, well-documented programs spanning the major VBP model types, including the Medicare Shared Savings Program, the Massachusetts Alternative Quality Contract, the Medicare Bundled Payments for Care Improvement initiative, the UK Quality and Outcomes Framework, and enhanced primary-care payment models; each source was individually verified against its publisher or bibliographic record before inclusion. Findings: VBP models produced modest but consistent reductions in low-value utilization, concentrated in post-acute and outpatient care, with savings that grew over multi-year program duration under stronger, two-sided risk arrangements. Evidence for improvement in incentivized process-of-care measures for diabetes, cardiovascular disease, and COPD was more consistent than evidence for corresponding reductions in mortality or major morbidity, and programs relying on financial incentives alone without dedicated care-coordination investment showed weaker results. Distributional analyses indicated that imperfect risk adjustment can disadvantage providers serving socioeconomically vulnerable chronic disease populations. Conclusions: Value-based payment can meaningfully reduce low-value utilization and improve process-of-care quality for chronic disease populations, but realizing durable clinical benefit requires sustained multi-year accountability, explicit investment in care-coordination infrastructure, and deliberate attention to social-risk adjustment rather than reliance on the payment mechanism alone.

Keywords: *value-based payment; accountable care organizations; bundled payments; chronic disease management; health economics evaluation*

Citation: Fabbri S, Stavrou K and Christiansen I (2025) Impact of Value-Based Payment Models on Chronic Disease Management Outcomes: A Health Economics Evaluation. Int J Health Policy Econ Manag, 3(1): 01-06.
DOI: 10.5281/zenodo.22656358

Corresponding Author: *Silvia Fabbri*

E-mail Address: *silvia.fabbri@universityofturin.edu*

Article History: *Received 12 January 2025 | Accepted 31 March 2025 | Published 21 June 2025*

Copyright: *© 2025 Silvia Fabbri, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (**https://creativecommons.org/licenses/by/4.0/**).*

Introduction

Chronic diseases — diabetes, cardiovascular disease, chronic obstructive pulmonary disease (COPD), and multimorbid combinations of these — account for the majority of health care spending in high-income countries and are disproportionately sensitive to how care is organized and reimbursed across the many providers who touch a single patient's care over time. Fee-for-service reimbursement, the dominant payment logic in most health systems for decades, rewards the volume of discrete services rather than the outcomes achieved across an episode or a population, an incentive structure widely regarded as poorly matched to conditions that require sustained primary care contact, medication management, self-management support, and coordination across specialists, hospitals, and post-acute settings [1]. Value-based payment (VBP) models — accountable care organizations (ACOs) with shared savings and shared risk, bundled or episode-based payments, pay-for-performance (P4P) programs that attach financial bonuses or penalties to quality metrics, and global or capitated budgets — were each designed, in different ways, to realign financial incentives toward the total cost and quality of care rather than the volume of billable encounters [2,3].

The empirical case for value-based payment in chronic disease management is not simple to establish, because the mechanisms by which these models are expected to improve outcomes — better care coordination, more preventive and guideline-concordant care, reduced avoidable hospitalization — operate through provider organizations whose size, risk tolerance, and existing care-management infrastructure vary enormously, and because the specific design of a given program (the quality metrics selected, the size of the financial incentive, whether risk is one-sided or two-sided, whether the population is attributed prospectively or retrospectively) materially shapes whether and how providers respond [4]. A substantial and maturing body of health economics and health services research has now evaluated named national and regional programs — the Medicare Shared Savings Program (MSSP) and Pioneer ACO models in the United States, the Massachusetts Alternative Quality Contract (AQC), the Medicare Bundled Payments for Care Improvement (BPCI) initiative, the UK Quality and Outcomes Framework (QOF), the Comprehensive Primary Care (CPC) initiative, and Michigan's Physician Group Incentive Program — each of which functions, in effect, as a large-scale natural policy experiment in value-based chronic disease management [5,6,7,8].

This article synthesizes that evidence as a case study of value-based payment's realized effects on chronic disease management outcomes, examining a defined set of well-documented programs in depth rather than surveying the payment-reform literature exhaustively. We organize the synthesis around three outcome domains that recur across essentially every program evaluated in this literature — health care spending and utilization, process and intermediate clinical quality, and care coordination together with distributional and implementation considerations — and we ask, within each domain, what the accumulated evidence from these specific cases indicates about the conditions under which value-based payment does and does not improve chronic disease outcomes, and at what cost.

Methods

This is a case-study-based narrative synthesis rather than a systematic review with a registered protocol or meta-analytic pooling of effect sizes. We selected for in-depth examination a purposive set of value-based payment programs that (a) have been evaluated in peer-reviewed health economics or health services research journals using quasi-experimental or randomized designs, (b) report outcomes specifically relevant to chronic disease populations (diabetes, cardiovascular disease, COPD, heart failure, or multimorbidity), and (c) collectively span the major model types of interest — global-budget ACO contracts, Medicare shared-savings ACOs, condition-based bundled payments, primary-care pay-for-performance, and enhanced primary-care payment models. Candidate studies were identified through targeted searches of PubMed/MEDLINE and Crossref-indexed journals using combinations of terms including "accountable care organization," "bundled payment," "pay-for-performance," "shared savings," "value-based payment," "chronic disease management," "diabetes," "cardiovascular," and "COPD," supplemented by citation tracking from key studies. Each candidate reference was individually verified against its publisher or Crossref/PubMed record (author list, journal, volume, issue, pagination, and DOI) before inclusion; sources that could not be independently verified were excluded. Because the aim is case-based conceptual and empirical synthesis rather than effect-size pooling, no formal risk-of-bias scoring or meta-analysis was performed; instead, findings from each program are presented with the study design used to generate them (difference-in-differences, regression discontinuity, instrumental variables, or randomized evaluation) so that the strength of the underlying causal inference is transparent to the reader.

Value-Based Payment Models: Structures and Adoption in Chronic Disease Care

The programs examined in this synthesis differ substantially in how they attach financial consequences to cost and quality, and these structural differences matter directly for chronic disease populations because they determine which actor bears risk for the higher, more variable costs that multimorbid patients generate. The Medicare Shared Savings Program enrolls physician-led or hospital-led ACOs that remain paid fee-for-service but become eligible for a share of savings (and, in two-sided tracks, liable for a share of losses) measured against a risk-adjusted spending benchmark for their attributed beneficiary population; early evaluations found that independent primary-care-led ACOs achieved larger savings than hospital-integrated ACOs, a pattern replicated in the Pioneer ACO model and attributed to primary-care organizations' comparative advantage in reducing referral-sensitive and post-acute utilization for chronic disease patients [5,9]. The Massachusetts Alternative Quality Contract combined a global population budget with substantial two-sided risk and an unusually large quality bonus tied to process and outcome measures, including several specific to diabetes and cardiovascular risk-factor control, and represents one of the more risk-concentrated commercial ACO designs evaluated to date [2,10].

Bundled or episode-based payment models take a structurally different approach, holding a single accountable entity — typically a hospital — financially responsible for the total cost of a defined clinical episode spanning an index admission and a fixed post-acute window, rather than for a population's total annual spending. The Medicare Bundled Payments for Care Improvement (BPCI) initiative extended this logic to medical (non-surgical) episodes including congestive heart failure, COPD exacerbation, and sepsis, testing whether episode-level financial accountability could improve coordination between inpatient and post-acute chronic disease care specifically [11,12]. Pay-for-performance programs, by contrast, leave the underlying payment mechanism largely intact and instead attach a bonus or penalty directly to measured performance on specified quality indicators; the UK's Quality and Outcomes Framework (QOF), introduced in 2004, is the largest and most extensively studied example, tying a substantial share of general practice income to achievement on more than one hundred indicators heavily weighted toward chronic disease management — blood pressure control, glycated hemoglobin monitoring, cholesterol management, and structured annual review for patients with diabetes, coronary heart disease, and COPD [6]. Enhanced primary-care payment models such as the Comprehensive Primary Care (CPC) initiative and Michigan's Physician Group Incentive Program occupy an intermediate position, layering care-management fees and performance incentives onto fee-for-service primary care specifically to fund the staffing (care managers, registries, self-management support) that chronic disease management is thought to require [7,8]. Table 1 summarizes the structural logic, financial-risk allocation, and chronic-disease-relevant design features of each model class examined in this synthesis.


Structural comparison of value-based payment model types applied to chronic disease management, including financial-risk allocation and chronic-disease-relevant design features.

Model type (example program)	Payment logic	Financial risk allocation	Chronic-disease-relevant design feature	Key reference
Shared-savings ACO (Medicare Shared Savings Program)	Fee-for-service base with retrospective shared savings/losses against a risk-adjusted spending benchmark	One- or two-sided risk borne by the ACO relative to benchmark	Rewards reduced referral-sensitive and post-acute utilization for attributed chronic disease population	McWilliams et al. 2016
Global-budget ACO (Massachusetts Alternative Quality Contract)	Prospective population budget with substantial two-sided risk and quality bonus	High provider-borne risk, larger and more durable incentive	Explicit diabetes and cardiovascular risk-factor quality gate tied to bonus eligibility	Song et al. 2012; Song et al. 2019
Condition-based bundled payment (Medicare BPCI medical bundles)	Retrospective reconciliation against an episode price for a defined clinical episode	Hospital-borne risk for total episode spending, including post-acute care	Applied to congestive heart failure, COPD exacerbation, and other medical (non-surgical) chronic episodes	Joynt Maddox et al. 2018; Rolnick et al. 2020
Pay-for-performance (UK Quality and Outcomes Framework)	Fee/capitation base with bonus tied to achievement on quality indicators	Low financial risk; upside-only bonus on measured indicators	Indicators heavily weighted toward diabetes, coronary heart disease, and COPD structured review	Doran et al. 2006
Enhanced primary-care payment (Comprehensive Primary Care Initiative; Michigan Physician Group Incentive Program)	Fee-for-service base plus per-member care-management fee and performance incentive	Low provider risk; fee funds care-management infrastructure directly	Funds registries, care managers, and self-management support specific to chronic disease population	Dale et al. 2016; Lemak et al. 2015

Cost and Utilization Outcomes Under Value-Based Payment

Across the programs reviewed, the most consistent and best-replicated finding is that value-based payment models produce modest, rather than transformative, reductions in total spending, concentrated in specific utilization categories rather than uniformly across all services. In the Medicare Shared Savings Program's first years, McWilliams and colleagues found savings of approximately 1.4 percent of benchmark spending among ACOs entering in 2012, driven primarily by reduced acute hospital and post-acute care use, with negligible savings in the cohort entering a year later, suggesting that early, more experienced or more motivated entrants captured most of the realized savings [5]. The Massachusetts Alternative Quality Contract, which imposed considerably stronger two-sided risk than the Medicare shared-savings tracks, produced larger and more durable effects: Song and colleagues documented savings that grew from roughly 2 percent in the second year to approximately 11 percent of medical spending by the eighth year of the contract, with savings increasingly concentrated in outpatient procedures, imaging, and post-acute care rather than primary care visits themselves [2,10]. This trajectory — savings that emerge gradually and compound as providers restructure referral patterns and post-acute utilization rather than through one-time reductions — recurs across the shared-savings and global-budget literature and is difficult to detect in evaluations limited to only the first one or two contract years.

Illustrative episode/benchmark spending change and post-acute utilization change reported across selected value-based payment programs for chronic disease episodes and populations, showing savings concentrated in post-acute and outpatient categories relative to acute inpatient care (McWilliams et al., 2016; Song et al., 2019; Rolnick et al., 2020).



Episode-based bundled payment for chronic medical conditions has generally produced smaller total-spending effects than ACO models, and the evidence is more mixed regarding whether savings are accompanied by any quality trade-off. Joynt Maddox and colleagues' evaluation of Medicare's medical-condition bundles found no significant reduction in total episode spending for congestive heart failure, COPD, or the other included conditions, alongside no significant change in mortality or readmission, indicating that hospitals largely failed to identify actionable savings opportunities for lower-margin medical episodes in the program's initial years [11]. A subsequent three-year evaluation using a longer follow-up window found modest savings of roughly 1.2 percent in total episode spending, achieved primarily through reduced skilled nursing facility utilization and increased use of home health services, with stable ninety-day mortality — a pattern broadly consistent with the ACO literature's finding that savings, when they materialize, tend to come from shifting post-acute care intensity downward rather than from reducing acute inpatient care itself [12]. Figure 1 summarizes illustrative spending and post-acute utilization changes reported across several of the programs reviewed, showing the concentration of savings in post-acute and outpatient categories relative to more limited effects on acute hospitalization.

Enhanced primary-care payment models targeted specifically at chronic disease infrastructure show a distinct cost pattern: care-management fees and shared-savings opportunities under the CPC initiative were largely offset by the fees themselves in the


program's first two years, producing no net reduction in total Medicare spending despite modest reductions in emergency department visits, a finding that underscores how the added cost of care-management infrastructure can erode measured net savings even when utilization moves in the intended direction [7]. Michigan's Physician Group Incentive Program, which combined care-management payments with performance incentives across a large multi-payer primary-care population, reported reduced total spending alongside improved quality performance, suggesting that multi-payer scale and sustained program duration may be relevant conditions for enhanced primary-care payment to generate net savings rather than simply redistributing spending toward care-management fees [8].

Quality of Care and Clinical Outcomes for Chronic Disease Populations

Evidence on quality and clinical outcomes presents a more heterogeneous picture than the spending literature, with effects that depend heavily on the specific measure examined, the strength of the underlying financial incentive, and how long the program has been in place. The literature's most direct evaluation of pay-for-performance in chronic disease management, the UK's QOF, produced substantial improvements in the specific process measures directly incentivized — blood pressure and glycemic monitoring rates rose sharply following the program's 2004 introduction — but subsequent long-term evaluations found that these process gains did not translate into a detectable reduction in mortality that could be attributed to the incentive itself, and that outcomes for some non-incentivized aspects of care showed no corresponding improvement or, in a subset of measures, modestly worsened as practices reallocated effort toward rewarded indicators [6,13]. A related spatial whole-population analysis of English primary care found that areas with higher measured QOF achievement did not show correspondingly lower premature mortality once socioeconomic deprivation was accounted for, reinforcing the conclusion that process-measure improvement under pay-for-performance does not reliably imply commensurate gains in population-level chronic disease outcomes [14].

Systematic reviews of the broader pay-for-performance literature reach a converging conclusion: Mendelson and colleagues' review found small-to-moderate improvements in process-of-care measures across the programs studied but generally weak, inconsistent, or absent evidence of improvement in intermediate clinical outcomes such as blood pressure or glycemic control, and essentially no consistent evidence of mortality benefit [15]. Petersen and colleagues' earlier review reached a similar assessment, finding that explicit financial incentives were associated with improved processes of care more consistently than with improved intermediate or final health outcomes [16]. Markovitz and Ryan's synthesis of this literature argues that the frequently cited "disappointing" average effect of pay-for-performance programs may mask substantial underlying heterogeneity by program design — incentive size, measure selection, baseline performance, and whether incentives are structured as thresholds or continuous scales — such that pooled null or small average effects understate the potential of well-designed programs while overstating the likely benefit of poorly designed ones [4]. Kondo and colleagues' complementary review of implementation processes found that programs providing performance feedback, data infrastructure, and technical assistance alongside the financial incentive showed more consistent quality improvement than programs relying on the incentive alone, suggesting that the payment mechanism functions as a necessary but insufficient condition for quality improvement absent complementary organizational investment [17].

Illustrative directional change in incentivized process-of-care measures versus hard clinical outcomes (mortality) across pay-for-performance and accountable care organization programs reviewed, showing a consistent gap between process-measure gains and demonstrated mortality benefit (Doran et al., 2006; Ryan et al., 2016; Kaufman et al., 2019).



ACO and global-budget models, which combine broader shared-savings incentives with quality gates that determine eligibility for shared savings, show comparatively more encouraging results specifically for chronic-disease-relevant process measures. The Alternative Quality Contract's evaluation found improvements in several diabetes and cardiovascular risk-factor management measures that grew over the contract's duration, alongside its documented spending reductions, suggesting that the combination of population-based financial accountability with an explicit quality gate may better align cost and quality incentives than pay-for-performance bonuses layered onto an unchanged fee-for-service base [10]. Kaufman and colleagues' systematic review of ACO evaluations across Medicare, Medicaid, and commercial payers similarly found the most consistent associations to be reductions in emergency department visits and inpatient use alongside improvements in preventive-care and chronic-disease-management process measures, a pattern replicated across payer types more consistently than pooled pay-for-performance evaluations show [18]. Figure 2 summarizes illustrative directional findings on process-of-care and intermediate outcome measures across the program types reviewed, highlighting the consistent gap between process-measure improvement and demonstrated mortality or hard-outcome benefit.

Care Coordination, Equity, and Implementation Considerations

Beyond aggregate cost and quality effects, the case evidence reviewed here points to two recurring implementation issues specific to chronic disease populations. The first concerns care coordination infrastructure: programs that funded care-management staffing and population registries directly, rather than relying solely on a retrospective shared-savings or bonus payment, more consistently reported improved chronic-disease-specific process measures, consistent with the general finding that the financial incentive alone is insufficient without complementary care-delivery investment [17,8]. Structural analyses of the bundled-payment approach to chronic

disease episodes reach a related conclusion from a different angle: the Dutch experience with disease-management-oriented bundled payments for diabetes and vascular risk management, introduced specifically to fund multidisciplinary primary-care teams, illustrates that bundled payment can be designed around chronic disease coordination directly rather than around a discrete acute episode, though evaluations of this model found that realized savings depended heavily on how care groups organized subcontracted specialist and allied-health services within the bundle [3]. Broader systematic evidence on disease-management-oriented financial arrangements similarly finds that expenditure effects for diabetes, heart failure, and COPD populations are inconsistent across programs and are frequently confounded by concurrent investment in self-management support that is difficult to separate from the payment mechanism itself [19,20].

The second recurring issue concerns distributional and equity risk. Value-based payment models that base financial reward on absolute performance levels rather than improvement, or that risk-adjust benchmarks imperfectly for social risk factors, create a structural risk that providers serving more socioeconomically disadvantaged or clinically complex chronic disease populations are penalized for case-mix and social factors outside their control rather than rewarded or held harmless for the greater difficulty of managing such populations. Roberts, Zaslavsky, and McWilliams' evaluation of Medicare's Value-Based Payment Modifier found that physician groups serving larger shares of low-income beneficiaries were more likely to receive automatic downward payment adjustments under the program's quality-tiering methodology, independent of the actual quality of care delivered, a finding with direct implications for chronic disease populations who are disproportionately concentrated in exactly the practices most exposed to this risk [21]. Ryan's earlier commentary on this structural risk argued that value-based purchasing programs which fail to adequately adjust for the social and clinical complexity of a provider's patient population risk widening rather than narrowing disparities in chronic disease care, a concern that subsequent empirical evaluations of quality-tiering and shared-savings attribution methodologies have generally corroborated [22].

Discussion

Taken together, the case evidence reviewed here supports three general conclusions about the realized impact of value-based payment on chronic disease management outcomes. First, the strongest and most consistently documented effect across model types is on health care spending and utilization, not on hard clinical outcomes: nearly every program examined — the Medicare Shared Savings Program, the Alternative Quality Contract, BPCI's medical-condition bundles, and QOF — shows some evidence of reduced low-value utilization (post-acute care, avoidable emergency visits, unnecessary imaging), while evidence of corresponding mortality or major morbidity reduction attributable specifically to the payment mechanism is considerably weaker and, in several of the largest and best-designed evaluations, statistically indistinguishable from no effect [5,11,13]. This asymmetry is important for policy expectations: value-based payment appears substantially more reliable as a cost-containment and utilization-management tool for chronic disease populations than as a direct lever for improving intermediate or final clinical outcomes at the population level.

Second, program design and duration matter more than model category per se. The Alternative Quality Contract's growing savings and quality gains over eight years, contrasted with BPCI's null first-cycle findings that only became modestly positive after a longer follow-up window, indicate that many of these effects take years rather than months to materialize as provider organizations restructure referral networks, staffing, and post-acute relationships, and that early single-year evaluations common in this literature may systematically understate the eventual effect of a program that survives long enough to mature [10,11,12]. This has a direct implication for evaluation practice: policymakers and researchers should treat early-cycle null findings from a newly launched value-based payment program with caution rather than concluding prematurely that the model is ineffective.

Third, the evidence on equity and distributional risk suggests that value-based payment models are not neutral with respect to which chronic disease patients and which providers bear adjustment risk, and that this risk is not self-correcting without deliberate design attention to risk adjustment and social-risk stratification [21,22]. Policymakers seeking to scale value-based payment for chronic disease management should therefore prioritize three design features supported by this evidence: sufficiently strong and durable (multi-year) financial accountability to allow restructuring effects to emerge, explicit funding for care-coordination infrastructure rather than reliance on the incentive payment alone to generate that infrastructure, and social-risk-adjusted benchmarking or quality-tiering methodologies that do not penalize providers for serving disadvantaged chronic disease populations.

This synthesis has several limitations. As a case-based narrative synthesis rather than a systematic review or meta-analysis, the selection of programs, while purposive and covering the major model types, is not exhaustive, and the quantitative findings drawn from different studies use heterogeneous outcome definitions, follow-up windows, and comparison groups that should not be pooled or directly compared as though drawn from a single measurement framework; they are presented here as illustrative of documented directional patterns within each case. Most of the evidence base concerns the United States and United Kingdom, where the largest and longest-running national programs have been implemented and evaluated, and generalization to other health system contexts should be made cautiously. Finally, because value-based payment programs continue to evolve — most of the U.S. Medicare programs reviewed here have undergone multiple redesigns since the evaluation periods reported — some conclusions drawn from earlier program iterations may not fully describe the incentive structures currently in effect.

Conclusion

Value-based payment models have produced a genuine, if more modest than originally anticipated, impact on chronic disease management: consistent evidence across accountable care organizations, bundled payments, and pay-for-performance programs indicates real reductions in low-value utilization and improvements in incentivized process-of-care measures for diabetes, cardiovascular disease, and COPD populations, but comparatively weak and inconsistent evidence of improvement in hard clinical outcomes such as mortality. The programs that have shown the largest and most durable effects — most notably the Massachusetts Alternative Quality Contract — combine strong, multi-year financial accountability with explicit quality gates and

sufficient time for provider organizations to restructure care delivery, while models relying on incentive payments alone, without complementary care-coordination investment or adequate social-risk adjustment, show weaker and less equitable results. Realizing the full potential of value-based payment for chronic disease management will likely require sustained program duration, deliberate investment in care-coordination infrastructure, and continued attention to the distributional consequences of how these models are designed, rather than reliance on the payment mechanism alone as a sufficient driver of better chronic disease outcomes.

References

1. Rosenthal MB, Frank RG (2006) What is the empirical basis for paying for quality in health care? Medical Care Research and Review, 63(2):135-157, DOI:10.1177/1077558705285291.

2. Song Z, Safran DG, Landon BE, He Y, Ellis RP, Mechanic RE, Day MP, Chernew ME (2012) The 'Alternative Quality Contract,' based on a global budget, lowered medical spending and improved quality. Health Affairs, 31(8):1885-1894, DOI:10.1377/hlthaff.2012.0327.

3. Struijs JN, Baan CA (2011) Integrating care through bundled payments - lessons from the Netherlands. New England Journal of Medicine, 364(11):990-991, DOI:10.1056/NEJMp1011849.

4. Markovitz AA, Ryan AM (2017) Pay-for-performance: disappointing results or masked heterogeneity? Medical Care Research and Review, 74(1):3-78, DOI:10.1177/1077558715619282.

5. McWilliams JM, Hatfield LA, Chernew ME, Landon BE, Schwartz AL (2016) Early performance of accountable care organizations in Medicare. New England Journal of Medicine, 374(24):2357-2366, DOI:10.1056/NEJMsa1600142.

6. Doran T, Fullwood C, Gravelle H, Gudex C, Hiroeh U, Hutchings A, Kristensen K, Roland M (2006) Pay-for-performance programs in family practices in the United Kingdom. New England Journal of Medicine, 355(4):375-384, DOI:10.1056/NEJMsa055505.

7. Dale SB, Ghosh A, Peikes DN, Day TJ, Yoon FB, Taylor EF, Swankoski K, O'Malley AS, Conway PH, Rajkumar R, Press MJ, Sessums L, Brown R (2016) Two-year costs and quality in the Comprehensive Primary Care Initiative. New England Journal of Medicine, 374(24):2345-2356, DOI:10.1056/NEJMsa1414953.

8. Lemak CH, Nahra TA, Cohen GR, Erb ND, Paustian ML, Share D, Hirth RA (2015) Michigan's fee-for-value physician incentive program reduces spending and improves quality in primary care. Health Affairs, 34(4):645-652, DOI:10.1377/hlthaff.2014.0426.

9. McWilliams JM, Landon BE, Chernew ME (2013) Changes in health care spending and quality for Medicare beneficiaries associated with a commercial ACO contract. JAMA, 310(8):829-836, DOI:10.1001/jama.2013.276302.

10. Song Z, Ji Y, Safran DG, Chernew ME (2019) Health care spending, utilization, and quality 8 years into global payment. New England Journal of Medicine, 381(3):252-263, DOI:10.1056/NEJMsa1813621.

11. Joynt Maddox KE, Orav EJ, Zheng J, Epstein AM (2018) Evaluation of Medicare's bundled payments initiative for medical conditions. New England Journal of Medicine, 379(3):260-269, DOI:10.1056/NEJMsa1801569.

12. Rolnick JA, Liao JM, Emanuel EJ, Huang Q, Ma X, Shan EZ, Dinh C, Zhu J, Wang E, Cousins D, Navathe AS (2020) Spending and quality after three years of Medicare's bundled payments for medical conditions: quasi-experimental difference-in-differences study. BMJ, 369:m1780, DOI:10.1136/bmj.m1780.

13. Ryan AM, Krinsky S, Kontopantelis E, Doran T (2016) Long-term evidence for the effect of pay-for-performance in primary care on mortality in the UK: a population study. Lancet, 388(10041):268-274, DOI:10.1016/S0140-6736(16)00276-2.

14. Kontopantelis E, Springate DA, Ashworth M, Webb RT, Buchan IE, Doran T (2015) Investigating the relationship between quality of primary care and premature mortality in England: a spatial whole-population study. BMJ, 350:h904, DOI:10.1136/bmj.h904.

15. Mendelson A, Kondo K, Damberg C, Low A, Motuapuaka M, Freeman M, O'Neil M, Relevo R, Kansagara D (2017) The effects of pay-for-performance programs on health, health care use, and processes of care: a systematic review. Annals of Internal Medicine, 166(5):341-353, DOI:10.7326/M16-1881.

16. Petersen LA, Woodard LD, Urech T, Daw C, Sookanan S (2006) Does pay-for-performance improve the quality of health care? Annals of Internal Medicine, 145(4):265-272, DOI:10.7326/0003-4819-145-4-200608150-00006.

17. Kondo KK, Damberg CL, Mendelson A, Motu'apuaka M, Freeman M, O'Neil M, Relevo R, Low A, Kansagara D (2016) Implementation processes and pay for performance in healthcare: a systematic review. Journal of General Internal Medicine, 31(Suppl 1):61-69, DOI:10.1007/s11606-015-3567-0.

18. Kaufman BG, Spivack BS, Stearns SC, Song PH, O'Brien EC (2019) Impact of accountable care organizations on utilization, care, and outcomes: a systematic review. Medical Care Research and Review, 76(3):255-290, DOI:10.1177/1077558717745916.

19. de Bruin SR, Baan CA, Struijs JN (2011) Pay-for-performance in disease management: a systematic review of the literature. BMC Health Services Research, 11:272, DOI:10.1186/1472-6963-11-272.

20. de Bruin SR, Heijink R, Lemmens LC, Struijs JN, Baan CA (2011) Impact of disease management programs on healthcare expenditures for patients with diabetes, depression, heart failure or chronic obstructive pulmonary disease: a systematic review of the literature. Health Policy, 101(2):105-121, DOI:10.1016/j.healthpol.2011.03.006.

21. Roberts ET, Zaslavsky AM, McWilliams JM (2018) The value-based payment modifier: program outcomes and implications for disparities. Annals of Internal Medicine, 168(4):255-265, DOI:10.7326/M17-1740.

22. Ryan AM (2013) Will value-based purchasing increase disparities in care? New England Journal of Medicine, 369(26):2472-2474, DOI:10.1056/NEJMp1312654.